NCT06389305View on ClinicalTrials.gov

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

NANot yet recruitingINTERVENTIONAL

Enrollment

213

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2026

Conditions

B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoid Leukemia

Interventions

DRUG

peripheral blood lymphocytes

autologous or allogeneic peripheral blood lymphocytes

DRUG

CIK cell

autologous or allogeneic cytokine-induced killer (CIK) cells

Trial Locations (1)

102206

Beijing GoBroad Hospital, Beijing

All Listed Sponsors

lead

Beijing GoBroad Hospital

OTHER

NCT06389305 - CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction | Biotech Hunter | Biotech Hunter